Peter C Adamson MD

PubMed

• Collaborative Innovations in Childhood Cancer Therapies.
  Iris Valtingojer, Sasha Lièvre, Philippe Bordes, Krupa Paranjpe, Winifred Thompson
  Handbook of Experimental Pharmacology. 2024-01-01
• 1 citations
  Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy.
  Kana Mizuno, Edmund V Capparelli, Tsuyoshi Fukuda, Min Dong, Peter C Adamson
  Clinical Pharmacology and Therapeutics. 2023-08-01
• 15 citations
  Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from ...
  Tamara P Miller, Kelly D Getz, Yimei Li, Biniyam G Demissei, Peter C Adamson
  The Lancet. Haematology. 2022-09-01

Journal Articles

• Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology...  
  Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, Krailo MD, Adamson PC, J Clin Oncol; 25(12):1512-8
• Population pharmacokinetics of fluconazole in young infants.  
  Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK, Jr., Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adamson PC, Gastonguay MR, Barrett JS, Antimicrob Agents Chemother; 52(11):4043-9
• Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.  
  Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G, Mehta MP, Neuro-oncology; 10(5):752-8
• Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.  
  Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC, J Clin Oncol; 26(22):3756-62
• Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation.  
  Robinson BW, Behling KC, Gupta M, Zhang AY, Moore JS, Bantly AD, Willman CL, Carroll AJ, Adamson PC, Barrett JS, Felix CA, Br J Haematol
• Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.  
  Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yam..., J Clin Oncol; 26(3):399-405
• A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.  
  Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson PC, Pediatr Blood Cancer; 50(3):577-80
• Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report.  
  Franklin JL, Seibel NL, Krailo M, Fu C, Adamson PC, Reaman G, Pediatr Blood Cancer; 50(3):533-6
• A rapid, sensitive and selective liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry method for determination of fenretinide (4-HPR...  
  Lee JI, Nguyen VT, Chen ML, Adamson PC, J Chromatogr B Analyt Technol Biomed Life Sci; 862(1-2):64-71
• A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non Hodgkin's Lymphoma: A Children's Oncology Grou...  
  Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, Vande Ven C, Perkins SL, Cairo MS, Clin Cancer Res; 13(18):5652s-60s
• Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.  
  Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M, Pediatr Blood Cancer; 49(3):352-7
• Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborativ...  
  Jacobs SS, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Erdmann G, Franklin J, Neglia JP, Steinberg SM, Balis FM, Adamson PC, Pediatr Blood Cancer; 49(3):250-5
• A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with c...  
  Lee JI, Skolnik JM, Barrett JS, Adamson PC, J Mass Spectrom; 42(6):761-70
• Discrete event simulation applied to pediatric phase I oncology designs.  
  Barrett J, Skolnik J, Jayaraman B, Patel D, Adamson P, Clin Pharmacol Ther; 84(6):729-33
• Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.  
  Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC, J Clin Oncol; 25(12):1505-11
• Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report.  
  Fouladi M, Furman WL, Chin T, Freeman BB, 3rd, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM, J. Clin. Oncol; 24(22):3678-85
• A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's...  
  Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM, Clin. Cancer Res;12(6):1750-9
• A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer.  
  Skolnik JM, Barrett JS, Shi H, Adamson PC, Cancer Chemother Pharmacol; 57(4):458-464
• Anticancer effects of fenretinide in human medulloblastoma.  
  Damodar Reddy C, Guttapalli A, Adamson PC, Vemuri MC, O'Rourke D, Sutton LN, Phillips PC, Cancer Lett; 231(2):262-269
• The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs.  
  Galinkin JL, Kurth CD, Shi H, Priestley MA, Loepke AW, Adamson PC, Biopharm Drug Dispos 2004;25(6):265-71
• Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.  
  Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N, Antimicrob Agents Chemother; 48(6):2166-72
• Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.  
  Adamson PC, Blaney SM, Widemann BC, Kitchen B, Murphy RF, Hannah AL, Cropp GF, Patel M, Gillespie AF, Whitcomb PG, Balis FM, Cancer Chemother Pharmacol; 53(6):482-8
• Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.  
  Thompson P, Balis F, Serabe BM, Berg S, Adamson P, Klenke R, Aiken A, Packer R, Murry DJ, Jakacki R, Blaney SM, Cancer Chemother Pharmacol; 52(5):417-23
• Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers.  
  Ozpolat B, Lopez-Berestein G, Adamson P, Fu CJ, Williams AH, J Pharm Pharm Sci; 6(2):292-301
• Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis.  
  Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM, J Clin Oncol; 21(1):143-7
• Join now to see all

Books/Book Chapters

• Making better drugs for children with cancer. 
  National Cancer Policy Board (U.S.). Committee on Shortening the Time Line for New Cancer Treatments., Adamson PC, Weiner SL, Simone JV, Gelband HNational Academies Press, Washington, D.C
• Pediatric secrets. 
  Chapter: Oncology 
  Page 514 - 543Aplenc R, Skolnik J, Adamson PCEditors: Polin RA, Ditmar MF.Mosby, PhiladelphiaEdition 4th,
• Cancer in children. 
  Chapter: Future trends in cancer chemotherapy 
  Page 56 - 67Fox E, Adamson PCEditors: Voute PA, Barrett A, Stevens MCG, Caron HN.Oxford University Press, OxfordEdition 5th,
• Principles and practice of pediatric oncology. 
  Chapter: General principles of chemotherapy 
  Page 290 - 365Adamson PC, Balis FM, Berg S, Blaney SMEditors: Pizzo PA, Poplack DG.Lippincott Williams & Wilkins, PhiladelphiaEdition 5th,
• Treatment of Acute Leukemias: New Directions for Clinical Research. 
  Chapter: Antipurines in Childhood Acute Lymphoblastic Leukemia 
  Page 297 - 308Gaynon P, Adamson PEditors: Pui C-H.Humana Press, Totowa
• Treatment of Acute Leukemias: New Directions for Clinical Research. 
  Chapter: Antipurines in Childhood Acute Lymphoblastic Leukemia 
  Page 395 - 403Gaynon P, Adamson PHumana Press, Totowa
• Conn's Current Therapy 2000. 
  Chapter: Acute leukemia in children 
  Page 421 - 425Adamson PCEditors: Rakel RE.WB Saunders, PhiladelphiaEdition 52nd,
• Oncology. 
  Chapter: Pediatric solid tumors 
  Page 385 - 413Adamson PC, Widemann BCEditors: Spence RAJ, Johnston PG.Oxford University Press, Oxford
• Pediatric secrets. 
  Chapter: Oncology 
  Page 575 - 611Langmuir P, Aplenc R, Adamson PCEditors: Polin RA, Ditmar. MF.Hanley & Belfus, PhiladelphiaEdition Thir,
• Handbook of Anti-Cancer Drug Development. 
  Chapter: Phase I Trial Design: Considerations in the Pediatric Population 
  Page 297 - 308Fox E, Adamson PCEditors: Budman D, Calvert H, Rowsinki E.Lippincott Williams & Wilkins
• Cancer in Children and Adolescents. 
  Chapter: Fundamentals of Cancer Chemotherapy 
  Page 95 - 112Widemann BC, Adamson PCEditors: Carroll WL, Finlay JL.Jones and Bartlett, Boston
• Drug resistance in leukemia and lymphoma: The clinical value of laboratory studies. 
  Chapter: Pharmacologic factors involved in the response to chemotherapy: apparent versus intrinsic drug resistance 
  Page 33 - 39Adamson P, Poplack DEditors: Kaspers GJL, Pieters R, Twentyman PR, Wiesenthal LM, Veerman AJP.Harwood Academic Publishers, Chur, Switzerland
• Cancer in the Nervous System. 
  Chapter: Pharmacologic approaches to treatment of meningeal metastases 
  Page 291 - 301Adamson PC, Poplack DGEditors: Levin VA.Churchill Livingstone, New York
• Join now to see all

Abstracts/Posters

• Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial.
  Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis FM, Blaney SM, ASCO Meeting Abstracts
• Treatment of relapse in childhood acute lymphoblastic leukemia. Acute lymphoblastic leukemia.
  Adamson PC, The cutting edge
• Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncol...
  Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Whitlock JA, Adamson PC, Hunger SP, Carroll WL, ASH Annual Meeting Abstracts; 118(21):573. PMID
• Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the...
  Aplenc R, Fisher BT, Sung L, Keren R, Alonzo TA, Hall M, Huang Y-SV, Li Y, Luan X, Gerbing RB, Bertoch D, Seif AE, Adamson PC, Gamis AS, ASH Annual Meeting Abstracts:118(21):2617. PMID
• Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial.
  Glade Bender JL, Lee A, Adamson PC, Ingle AM, Ahern CH, Wu B, Baruchel S, Harris PJ, Ames MM, Weigel B, Blaney S, Children's Oncology Group, ASCO Meeting Abstracts; 29(15_suppl):9501. PMID
• Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study.
  Warwick AB, Malempati S, Krailo MD, Melemed AS, Adamson PC, Blaney S, ASCO Meeting Abstracts; 28(15_suppl):9535. PMID
• A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study.
  Park JR, Hawkins DS, Ingle M, Borinstein SC, Glade Bender JL, Yamashiro D, Baruchel S, Chen AP, Adamson PC, Blaney S, ASCO Meeting Abstracts; 28(15_suppl):9530. PMID
• A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Cons...
  Mosse YP, Lipsitz EG, Maris JM, Weigel B, Adamson PC, Ingle M, Ahern CH, Blaney S, ASCO Meeting Abstracts; 28(15_suppl):9529
• Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB).
  Lipsitz EG, Nguyen V, Zhao H, Ecsedy J, Maris JM, Adamson PC, Mosse YP, ASCO Meeting Abstracts; 28(15_suppl):10593. PMID
• Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group Phase I Consortium.
  Aplenc R, Strauss LC, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Blaney SM, Adamson PC, ASCO Meeting Abstracts;26(15_suppl):3591
• Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children...
  Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC, ASCO Meeting Abstracts
• A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study.
  Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Jr, Fox FE, Voss S, Adamson PC, Blaney SM, ASCO Meeting Abstracts
• Phase I and pharmacokinetic (PK) study of lenalidomide (LEN) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndrome (MDS): A Children'...
  Berg SL, Russell H, Cairo M, Ingle AM, Adamson PC, Blaney SM, ASCO Meeting Abstracts;27(15S):10023
• Pediatric phase I trial and pharmacokinetic (PK) study of ispinesib (SB715992): A Children's Oncology Group phase I consortium study.
  Souid A, Dubowy RL, Greenwald Triplett D, Ingle AM, Sun J, Blaney SM, Adamson PC, Meeting Abstracts;26(15_suppl):10014
• Phase I trial and pharmacokinetics (PK) of lenalidomide in pediatric patients with relapsed/refractory solid tumors or MDS: A Children's Oncology Group phase I consort...
  Russell H, Cairo MS, Blaney SM, Adamson PC, Ingle AM, Berg S, ASCO Meeting Abstracts; 26(15_suppl):13532
• Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
  Jacobs S, Fox B, Krailo MD, Hartley G, Navid F, Wexler L, Blaney SM, Frank B, Adamson PC, Widemann BC, ASCO Meeting Abstracts; 26(15_suppl):10026
• A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medull...
  Fouladi M, Park JR, Sun J, Ingle AM, Ames MM, Stewart CF, Gilbertson R, Zwiebel JA, Adamson PC, Blaney SM., ASCO Meeting Abstracts;26(15_suppl):10012
• A pediatric phase I trial and pharmacokinetic (PK) study of sunitinib: A Children's Oncology Group Phase I Consortium study.
  DuBois SG, Shusterman S, Ingle AM, Baruchel S, Stempak D, Sun J, Ivy SP, Glade-Bender J, Blaney SM, Adamson PC, Children's Oncology Group Phase C, ASCO Meeting Abstracts; 26(15_suppl):3561
• Join now to see all

Lectures

• Restructuring the Children’s Oncology Group Clinical Research Enterprise. 
  Texas Children’s Cancer Center Grand Rounds, Houston, TX
• New Oncology Drug Development for Children and Adolescents in Europe: Where are we after 5 years of the EU Paediatric Medicine Regulation? Where to Go? 
  Biotherapy Development Association Workshop, London, England
• Development of Targeted New Agents for Children with Cancer. 
  Melissa Ann Krinsky Memorial Lecture, Detroit, MI
• Teach Your Parents Well: Leads from Childhood Cancer Research. 
  Karmanos Cancer Institute Grand Rounds, Detroit, MI
• Development of Targeted Agents for Children with Cancer. 
  Lund, Sweden, 2011; Moscow, Russia, 2011
• Clinical Trials Experience With Cardiac Safety. 
  Cardiac Safety Research Consortium, White Oak Facility, FDA Headquarters Silver Springs, MD
• Clinical Development of Immunotherapy: A View from the COG. 
  2nd International Conference on Immunotherapy in Pediatric Oncology, Houston, TX
• Teach Your Parents Well: Personalized Rx in Children with Cancer. 
  Personalized Cancer Therapeutics Fall Symposium, University of Chicago Chicago, IL
• Childhood Cancer Research: 21st Century Science, 20th Century Clinical Trials. 
  Kansas City, MO, 2010; Minneapolis, MN, 2010; Seattle, WA, 2010; Birmingham, AL, 2011, Boston, MA
• Phase 1 Trials in Children with Cancer. 
  Accelerating Anticancer Agent Development and Validation FDA-AACR Workshop, Bethesda, MD
• Restructuring the COG Clinical Trials Enterprise. 
  Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
• Targeted Drug Development for Children with Cancer. 
  Israeli Society Pediatric Hematology Oncology, K Ginossar, Israel
• Strategies to Improve Intrathecal Therapy. 
  American Society Pediatric Hematology Oncology, Montreal, Canada
• Childhood Cancer. 
  Cancer Policy Roundtable National Coalition for Cancer Survivorship, Washington, DC
• Childhood Cancer Research. 
  Wilmington, DE, 2010; Washington, DC, 2010
• Signal Transduction Inhibitors for Childhood Cancer: The Children's Oncology Group Experience. 
  Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
• Drug formulations for children with cancer: What’s old is new again. 
  FDA Oncology Drug Advisory Pediatric Subcommittee, Bethesda, MD
• Cancer Drug Development: 21st Century Science, 20th Century Clinical Trials. 
  Houston, TX, 2009, 2010
• Early Phase Drug Development in Children. 
  20th Annual EORTC-NCI-AACR Meeting, Geneva, Switzerland
• Leveraging Opportunities: The Importance of Pediatric Study Design. 
  American College of Clinical Pharmacology 37th Annual Meeting, Philadelphia, PA
• Imaging in Early Phase Childhood Cancer Trials. 
  ALARA Concept in Pediatric Imaging Annual Meeting, Scottsdale, AZ
• New Agents for Children with Cancer. 
  Pediatric Grand Rounds, Denver, CO
• Development of Targeted Therapy for Children with Cancer. 
  Ely Brent Visiting Professor The Children’s Hospital, Denver Cancer Center Rounds
• Early Phase Cancer Drug Development in Children. 
  Philadelphia, PA, 2007; Boulder, CO, 2008
• Drug Development for Children with Cancer. 
  Children's Neuroblastoma Cancer Foundation Meeting Chicago, IL
• Join now to see all